Fig. 3: Relative ctDNA scores in serial blood draws over the course of treatment. | npj Precision Oncology

Fig. 3: Relative ctDNA scores in serial blood draws over the course of treatment.

From: Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

Fig. 3: Relative ctDNA scores in serial blood draws over the course of treatment.The alternative text for this image may have been generated using AI.

Swimmer plots depicting on-treatment ctDNA score relative to the baseline ctDNA score in available serial blood draws over the course of treatment in each patient eligible for analysis of ctDNA change from baseline to C3 (n = 183 samples from 58 patients). Each row represents a unique patient participant (y-axis) where patients are grouped by ctDNA score status at cycle 3 and ordered by total length of follow-up since treatment initiation (x-axis, months). Patients with a ctDNA score <baseline ctDNA score at cycle 3 (n = 29) (blue circles; left panel) and patients with a ctDNA score >baseline ctDNA score at cycle 3 (n = 29) (pink circles; right panel) are shown. Black circles indicate baseline ctDNA samples, triangles indicate disease progression, ‘X’ indicates death events, and tick marks represent last follow-up.

Back to article page